Outsourcing Uncovering the CRDMO advantage
Bringing a new drug to market is always complicated, especially when working with multiple outsourcing partners. As a result, we are seeing a shift towards integrated CROs and CDMOs, which can offer everything from drug discovery to clinical trials under one roof. Abi Millar
speaks to Kevin Li, chief marketing offi cer of BioDuro-Sundia, and Jennifer Cannon, president commercial operations pharma services at Thermo Fisher Scientifi c, to fi nd out more.
n today’s pharmaceutical landscape, outsourcing to third parties has become the norm. A pharma company might entrust their manufacturing services to a contract development and manufacturing organisation (CDMO) or offload their research to a contract research organisation (CRO). Doing so enables them to focus on their own areas of expertise, while benefitting from their partner’s niche know-how, specialist equipment or regional presence. With big pharma now outsourcing around half its R&D activities (or even more in the case of smaller companies), the trend isn’t going anywhere.
I
According to Grand View Research, the global biotechnology and pharmaceutical outsourcing market size stood at $46bn in 2023. It is projected to grow by 5.5% a year between now and 2030, to reach almost $70bn. It’s easy to see why this is happening. As drug development becomes more complex, it simply isn’t feasible for pharma companies (especially smaller biotechs) to perform all functions in-house. Equally, though, a highly fractured outsourcing market – populated by thousands of small, hyper- specialised service providers – probably isn’t sustainable. We’re seeing a concurrent trend towards
12
Clinical Trials Insight /
www.worldpharmaceuticals.net
Mahir KART/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37
